The molecular basis of Costello syndrome

Monographs in Human Genetics

Volumn 17, Issue , 2009, Pages 94-103

  Sol Church, K ^a   Gripp, K W ^a  

^a NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84857722887     PISSN: 00770876     EISSN: 16623835     Source Type: Book Series    
DOI: 10.1159/000164845     Document Type: Article

References (42)

1. Tartaglia M, Mehler EL, Goldberg R, Zampino G, Brunner HG, et al: Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome. Nat Genet 2001;29:465-468. (Pubitemid 34326699)
2. Tartaglia M, Cotter PD, Zampino G, Gelb BD, Rauen KA: Exclusion of PTPN11 mutations in Costello syndrome: Further evidence for distinct etiologies for Noonan, cardiofaciocutaneous and Costello syndrome. Clin Genet 2003;63:423-426. (Pubitemid 36944087)
3. Aoki Y, Niihori T, Kawame H, Kurosawa K, Ohashi H, et al: Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat Genet 2005;37:1038-1040. (Pubitemid 41486653)
4. Forbes S, Clements J, Dawson E, Bamford S, Webb T, et al: COSMIC 2005. Br J Cancer 2006;94:318-322. (Pubitemid 43151554)
5. Gripp KW, Lin AE, Stabley DL, Nicholson L, Charles I, et al: HRAS mutation analysis in Costello syndrome: genotype and phenotype correlation. Am J Med Genet A 2006;140:1-7. (Pubitemid 43054028)
6. Estep AL, Tidyman WE, Teitell MA, Cotter PD, Rauen KA: HRAS mutations in Costello syndrome: Detection of constitutional activating mutations in codon 12 and 13 and loss of wildtype allele in malignancy. Am J Med Genet A 2006;140:8-16. (Pubitemid 43054029)
7. Kerr B, Delrue MA, Sigaudy S, Perveen R, Marche M, et al: Genotype-phenotype correlation in Costello syndrome; HRAS mutation analysis in 43 cases. J Med Genet 2006;43:401-405.
8. Lin AE, Rauen KA, Gripp KW, Carey JC: Clarification of previously reported Costello syndrome patients. Am J Med Genet A 2008;146:940-943. (Pubitemid 351499803)
9. Sol-Church K, Stabley DL, Nicholson L, Gonzalez IL, Gripp KW: Paternal bias in parental origin of HRAS mutations in Costello syndrome. Hum Mutat 2006;27:736-741. (Pubitemid 44205066)
10. Van Steensel MA, Vreeburg M, Peels C, Van Ravenswaaij-Arts CM, Bijlsma E, et al: Recurring HRAS mutation G12S in Dutch patients with Costello syndrome. Exp Dermatol 2006;15:731-734. (Pubitemid 44145242)
11. Zampino G, Pantaleoni F, Carta C, Cobellis G, Vasta I, et al: Diversity, parental germline origin, and phenotypic spectrum of de novo HRAS missense changes in Costello syndrome. Hum Mutat 2007;28:265-272.
12. Van der Burgt I, Kupsky W, Stassou S, Nadroo A, Barroso C, et al: Myopathy caused by HRAS germline mutations - implications on disturbed myogenic differentiation in the presence of constitutive H-Ras activation. J Med Genet 2007;44:459-462. (Pubitemid 47056873)
13. Selcen D, Kupsky WJ, Benjamins D, Nigro MA: Myopathy with muscle spindle excess: A new congenital neuromuscular syndrome? Muscle Nerve 2001;24:138-143.
14. Pfeifer GP: p53 mutational spectra and the role of methylated CpG sequences. Mutat Res 2000;450:155-166. (Pubitemid 30323640)
15. Søvik O, Schubbert S, Houge G, Steine SJ, Norgård G, et al: De novo HRAS and KRAS mutations in two siblings with short stature and neuro-cardiofaciocutaneous features. J Med Genet 2007;44:e84.
16. Colby WW, Hayflick JS, Clark SG, Levinson AD: Biochemical characterization of polypeptides encoded by mutated human Ha-ras1 genes. Mol Cell Biol 1986;6:730-734. (Pubitemid 16165311)
17. Fasano O, Aldrich T, Tamanoi F, Taparowsky E, Furth M, Wigler M: Analysis of the transforming potential of the human H-ras gene by random mutagenesis. Proc Natl Acad Sci USA 1984;81:4008-4012. (Pubitemid 14054513)
18. Gripp KW, Innes AM, Axelrad ME, Gillan TL, Parboosingh JS, et al: Costello syndrome associated with novel germline HRAS mutations: An attenuated phenotype? Am J Med Genet A 2008;146:683-690. (Pubitemid 351354143)
19. Penrose LS: Parental age and mutation. Lancet 1955;2:312-313.
20. Lurie IW: Genetics of the Costello syndrome. Am J Med Genet 1994;52:358-359. (Pubitemid 24280022)
21. Goriely A, McVean GA, Rojmyr M, Ingermarsson B, Wilkie AO: Evidence for selective advantage of pathogenic FGFR2 mutations in the male germ line. Science 2003;301:606-607.
22. Goriely A, McVean GA, Van Pelt AM, O'Rourke AW, Wall SA, et al: Gain-offunction amino acid substitutions drive positive selection of FGFR2 mutations in human spermatogonia. Proc Natl Acad Sci USA 2005;102:6051-6056. (Pubitemid 40594253)
23. Lazaro C, Gaona A, Ainsworth P, Tenconi R, Vidaud D, et al: Sex differences in mutational rate and mutational mechanism in the NF1 gene in neurofibromatosis type 1 patients. Hum Genet 1996;98:696-699. (Pubitemid 26387959)
24. Lopez-Correa C, Dorschner M, Brems H, Lazaro C, Clementi M, et al: Recombination hotspot in NF1 microdeletion patients. Hum Mol Genet 2001;10:1387-1392. (Pubitemid 32640667)
25. Zampino G, Mastroiacovo P, Ricci R, Zollino M, Segni G, et al: Costello syndrome: Further clinical delineation, natural history, genetic definition, and nosology. Am J Med Genet 1993;47:176-183. (Pubitemid 23240687)
26. Johnson JP, Golabi M, Norton ME, Rosenblatt RM, Feldman GM, et al: Costello syndrome: phenotype, natural history, differential diagnosis, and possible cause. J Pediatr 1998;133:441-448. (Pubitemid 28413632)
27. Bodkin NM, Mortimer ES, Demmer LA: Male to male transmission of Costello syndrome consistent with autosomal dominant inheritance. Am J Hum Genet 1999;65(Suppl):A143.
28. Gripp KW, Stabley DL, Nicholson L, Hoffman JD, Sol-Church K: Somatic mosaicism for an HRAS mutation causes Costello syndrome. Am J Med Genet A 2006;140:2163-2169. (Pubitemid 44522430)
29. White SM, Graham JM Jr, Kerr B, Gripp K, Weksberg R, et al: The adult phenotype in Costello syndrome. Am J Med Genet A 2005;136:128-135. (Pubitemid 40967101)
30. Cohen JB, Broz SD, Levinson AD: Expression of the H-ras proto-oncogene is controlled by alternative splicing. Cell 1989;58:461-472. (Pubitemid 19203532)
31. Huang MY, Cohen JB: The alternative H-ras protein p19 displays properties of a negative regulator of p21Ras. Oncol Res 1997;9:611-621. (Pubitemid 127787912)
32. Bourne HR, Sanders DA, McCormick F: The GTPase superfamily: conserved structure and molecular mechanism. Nature 1991;349:117-127. (Pubitemid 21912023)
33. Pai EF, Kabsch W, Krengel U, Holmes KC, John J, Wittinghofer A: Structure of the guanine-nucleotide-binding domain of the Ha-ras oncogene product p21 in the triphosphate conformation. Nature 1989;341:209-214. (Pubitemid 19231720)
34. Pai EF, Krengel U, Petsko GA, Goody RS, Kabsch W, Wittinghofer A: Refined crystal structure of the triphosphate conformation of H-ras p21 at 1.35 Å resolution: implications for the mechanism of GTP hydrolysis. EMBO J 1990;9:2351-2359.
35. Vetter IR, Wittinghofer A: The guanine nucleotide-binding switch in three dimensions. Science 2001;294:1299-1304. (Pubitemid 33063089)
36. Oliva JL, Zarich N, Martinez N, Jorge R, Castrillo A, et al: The P34G mutation reduces the transforming activity of K-Ras and N-Ras in NIH 3T3 cells but not of H-Ras. J Bio Chem 2004;279:33480-33489.
37. Lowy DR, Willumsen BM: Function and regulation of Ras. Annu Rev Biochem 1993;62:851-891. (Pubitemid 23237890)
38. Ahmadian MR, Zor T, Vogt D, Kabsch W, Selinger Z, et al: Guanosine triphosphatase stimulation of oncogenic Ras mutants. Proc Natl Acad Sci USA 1999;96:7065-7070. (Pubitemid 29275010)
39. Tabin CJ, Bradley SM, Bargmann CI, Weinberg RA, Papageorge AG, et al: Mechanism of activation of a human oncogene. Nature 1982;300:143-149. (Pubitemid 12006346)
40. Reddy EP, Reynolds RK, Santos E, Barbacid M: A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature 1982;300:149-152. (Pubitemid 12006347)
41. Gripp KW, Lin AE, Nicholson L, Allen W, Cramer A, et al: Further delineation of the phenotype resulting from BRAF or MEK1 germline mutations helps differentiate cardio-facio-cutaneous syndrome from Costello syndrome. Am J Med Genet A 2007;143:1472-1480. (Pubitemid 47051026)
42. Rauen KA: Distinguishing Costello versus cardio-facio-cutaneous syndrome: BRAF mutations in patients with a Costello phenotype. Am J Med Genet A 2006;140:1681-1683. (Pubitemid 44148257)